Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more
Nanjing Vazyme Biotech Co Ltd (688105) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.17 Billion CNY
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has total liabilities worth CN¥1.17 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nanjing Vazyme Biotech Co Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nanjing Vazyme Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BELRISE INDUSTRIES LTD
NSE:BELRISE
|
India | ₹31.17 Billion |
|
Baota Industry Co Ltd
SHE:000595
|
China | CN¥8.39 Billion |
|
Shandong Sinobioway Biomedicine Co Ltd
SHE:002581
|
China | CN¥221.51 Million |
|
Lotte Energy Materials Corporation
KO:020150
|
Korea | ₩424.55 Billion |
|
Yunding Technology Co Ltd
SHE:000409
|
China | CN¥826.07 Million |
|
Jinxi Axle Co Ltd
SHG:600495
|
China | CN¥760.99 Million |
|
COHTF
PINK:COHTF
|
USA | $247.03 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Nanjing Vazyme Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanjing Vazyme Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanjing Vazyme Biotech Co Ltd (2017–2024)
The table below shows the annual total liabilities of Nanjing Vazyme Biotech Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.11 Billion | -35.64% |
| 2023-12-31 | CN¥1.72 Billion | +23.24% |
| 2022-12-31 | CN¥1.39 Billion | +190.33% |
| 2021-12-31 | CN¥479.83 Million | +71.81% |
| 2020-12-31 | CN¥279.28 Million | +124.65% |
| 2019-12-31 | CN¥124.31 Million | +46.82% |
| 2018-12-31 | CN¥84.67 Million | +125.34% |
| 2017-12-31 | CN¥37.57 Million | -- |